Published in Oncogene on May 22, 1997
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
An overview of the c-MET signaling pathway. Ther Adv Med Oncol (2011) 1.95
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A (2006) 1.47
MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer (2012) 1.39
Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A (2001) 1.10
GDNF promotes tubulogenesis of GFRalpha1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase. J Cell Biol (2003) 1.08
Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell (2009) 1.06
RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia (2009) 1.04
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid (2013) 0.99
Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer (2012) 0.99
Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture. Br J Cancer (1999) 0.98
A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol (2010) 0.86
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol (2013) 0.81
The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth. Front Pharmacol (2012) 0.79
INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models. Sci Rep (2015) 0.78
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer (2015) 0.78
Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression. Oncotarget (2015) 0.78
Papillary carcinoma of the thyroid: methylation is not involved in the regulation of MET expression. Br J Cancer (2004) 0.76
Resistance of papillary thyroid cancer stem cells to chemotherapy. Oncol Lett (2016) 0.76
Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma. Oncogene (2016) 0.75
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases. Mol Diagn Ther (2017) 0.75
Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell (1999) 5.07
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol (1992) 5.04
Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol (1995) 4.60
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 4.10
Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. Exp Cell Res (1985) 3.41
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene (1991) 3.41
Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer (2006) 3.23
P53 in tumour pathology: can we trust immunocytochemistry? J Pathol (1992) 3.00
Tyrosine kinase receptor indistinguishable from the c-met protein. Nature (1989) 3.00
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (1998) 2.83
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J (1992) 2.65
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell (2001) 2.62
Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol (1997) 2.51
Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene (1991) 2.44
Plexin A is a neuronal semaphorin receptor that controls axon guidance. Cell (1998) 2.39
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene (2000) 2.27
Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts. Nat Genet (2000) 2.26
Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell (1996) 2.14
HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J (1996) 2.09
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J (1994) 2.04
Detection of phosphotyrosine-containing proteins in the detergent-insoluble fraction of RSV-transformed fibroblasts by azobenzene phosphonate antibodies. EMBO J (1984) 1.98
High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene (1989) 1.98
Monoclonal antibodies against murine gamma interferon. Proc Natl Acad Sci U S A (1984) 1.95
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer (1991) 1.95
Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene (1989) 1.92
The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol (1991) 1.90
Cell surface molecules and fibronectin-mediated cell adhesion: effect of proteolytic digestion of membrane proteins. J Cell Biol (1982) 1.90
Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell Biol (2000) 1.89
Cleavage of a 135 kD cell surface glycoprotein correlates with loss of fibroblast adhesion to fibronectin. Exp Cell Res (1985) 1.86
Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene (1994) 1.81
Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci (1998) 1.75
Overexpression of the RON gene in human breast carcinoma. Oncogene (1998) 1.73
The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem (1991) 1.71
Cross-talk between the proto-oncogenes Met and Ron. Oncogene (2000) 1.71
A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc Natl Acad Sci U S A (1992) 1.70
Characterisation of human thyroid epithelial cells immortalised in vitro by simian virus 40 DNA transfection. Br J Cancer (1989) 1.68
The transmembrane protein Off-track associates with Plexins and functions downstream of Semaphorin signaling during axon guidance. Neuron (2001) 1.68
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene (1995) 1.66
A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol (1996) 1.65
Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J (1997) 1.60
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene (1991) 1.58
A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene (2006) 1.56
Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. Proc Natl Acad Sci U S A (1993) 1.56
Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer (1993) 1.55
Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene (1992) 1.51
Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem (1993) 1.51
Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene (1994) 1.48
A 135,000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion. Immunofluorescence localization in normal and RSV-transformed fibroblasts. Exp Cell Res (1986) 1.48
Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem (1991) 1.48
Plexin signaling hampers integrin-based adhesion, leading to Rho-kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility. FASEB J (2004) 1.46
Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol Cell Biol (2000) 1.46
Activated ras oncogenes in human thyroid cancers. Cancer Res (1988) 1.45
A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Mol Cell Biol (1993) 1.44
The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell (1996) 1.42
Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene (2007) 1.42
HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol (1999) 1.41
Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res (1995) 1.40
Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A (1996) 1.37
Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer (1994) 1.36
Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer (1996) 1.35
Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene (1997) 1.34
Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science (1985) 1.30
Fibronectin-plasma membrane interaction in the adhesion of hemopoietic cells. J Cell Biol (1986) 1.29
The polymerase chain reaction: miracle or mirage? A critical review of its uses and limitations in diagnosis and research. J Pathol (1990) 1.29
Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem (1994) 1.26
Toxicology and epidemiology of 1,3-butadiene. Crit Rev Toxicol (1997) 1.26
Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. Oncogene (1996) 1.25
Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene (1996) 1.25
The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity. J Biol Chem (1987) 1.24
Uptake and incorporation of saturated and unsaturated fatty acids into macrophage lipids and their effect upon macrophage adhesion and phagocytosis. Biochem J (1990) 1.24
Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol Cell Biol (1999) 1.23
p145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line. Mol Cell Biol (1988) 1.22
Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. J Cell Biol (1994) 1.22
Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Thorax (1996) 1.22
Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene (1991) 1.20
Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum Mol Genet (2001) 1.20
Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol Cell Biol (1998) 1.19
Pathway specificity for Met signalling. Nat Cell Biol (2001) 1.19
Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer (1996) 1.18
Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res (2001) 1.18
Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells. Mol Cell Biol (1986) 1.17
Use of bromodeoxyuridine for cell kinetic studies in intact animals. Cell Tissue Kinet (1986) 1.17
Physical randomization of tissue architecture: an alternative to systemic sampling. J Microsc (1982) 1.17
Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene (2000) 1.15
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. Cell Mol Biol (Noisy-le-grand) (1994) 1.15
Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem (1994) 1.15
Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet Cytogenet (1992) 1.14
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene (1999) 1.14
A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci U S A (1996) 1.14
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J (2000) 1.13